3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
94
Neoplasm Metastasis
6
Breast Diseases
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Cancer Metastatic
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Primary Breast Cancer ER+ve
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Beast Cancer
1
Mammary Neoplasms, Animal
1
Locoregional Recurrence
1
Lethal Congenital Contracture Syndrome 2
1
Hyperglycemia
1
Hormone Receptor Positive Malignant Neoplasm of Breast
1
HER2-positive Breast Cancer
1
Granulosa cell tumor of the ovary
1
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
1
Endometrial Stromal Tumors
1
Endometrial Hyperplasia
1
ER+ Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Ductal
1
Bulbo-Spinal Atrophy, X-Linked
1
Interventions
exemestane
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mammary Neoplasms, Animal
×
exemestane
×
Clear all
NCT00676663
2022-05-11
ENCORE301
Syndax Pharmaceuticals
Phase 2
Completed
130 enrolled
18 charts